A young man with acute dilated cardiomyopathy associated with methylphenidate.
An 18-year-old obese man with a body mass index of 40, diagnosed with attention-defi cit hyperactivity disorder and treated with methylphenidate (Concerta®) was acutely admitted to hospital with hypoxia and dyspnoea. On investigation signs of liver-, renal-, and heart-failure were found. Noradrenalin infusion was started. Echocardiography showed dilated left ventricle and an ejection fraction (EF) of 25%. Liver function improved, noradrenalin and dobutamine were tapered, but three days after admission a new echocardiography showed an EF of 10%. The patient was transferred to the National Hospital (Rikshospitalet, Oslo), where intensifi ed treatment including intra aortic balloon pump (IABP) was instituted. Cardiac function improved, and 3 weeks later the IABP was disconnected. EF at this point was 15%. The patient was denied heart transplantation due to various cofactors. The investigation concluded with a probable relationship between his cardiomyopathy and the use of methylphenidate (Concerta).
PublisherDove Medical Press
CitationVascular Health and Risk Management (2008) 4(2), 477–479
The following license file are associated with this item: